Reported about 17 hours ago
Germany's Merck KGaA is reportedly in advanced discussions to acquire U.S.-based biotech company Springworks Therapeutics, which focuses on cancer and rare disease treatments. While details remain confidential, the acquisition could significantly enhance Merck's oncology pipeline. Springworks shares saw a notable increase following the news, although sources indicate other potential buyers may emerge. This transaction, if completed, would mark one of Merck's largest in recent years amid a resurgence of deal-making in the U.S. healthcare sector.
Source: YAHOO